On admission, patients of the no-COVID-19 group showed higher use of low dose aspirin (p < 0.001), P2Y12 inhibitors (p = 0.001), direct oral anticoagulants (p = 0.003) and statin (p < 0.001), whereas heparin use was more frequent among COVID-19 patients (p < 0.001). Here, P2RY12 is linked to COVID-19.